动脉粥样硬化是一种慢性进行性炎症性血管疾病,是许多心脑血管疾病发展的重要病理基础。传统的药物治疗和介入或手术治疗效果不佳,且有严重的并发症。尽管已经研究了多种抗动脉粥样硬化的靶物质,但如何将这些物质准确地递送到受损的血管内皮并保持其生物活性是一个重大挑战。最近的研究表明,合适的载体可以更好地解决这些问题,从而提供更安全,更有效和更具成本效益的治疗策略。Atherosclerosis is a chronic progressive inflammatory vascular disease that is an important pathological basis for the development of many cardiovascular diseases. Traditional pharmacological treatments and interventional or surgical treatments are ineffective and have serious complications. Although a variety of anti-atherosclerotic target substances have been investigated, it is a major challenge to accurately deliver these substances to the damaged vascular endothelium and to maintain their biological activity. Recent studies have shown that suitable carriers can better address these issues, thus providing safer, more effective and cost-efficient therapeutic strategies.
心血管疾病(cardiovascular disease, CVD)与糖尿病以及慢性肾脏病(chronic kidney disease, CKD)均是最常见的疾病。已有的流行病学研究与临床研究均有证据支持三者之间相互关联,并且定义了心脏–代谢–肾脏疾病CMR (cardio-metabolic-renal disease)这一概念。三者之间相互联系,相互影响,具有显著的流行病学、病理生理学和预后意义。既往研究发现高糖状态可以诱发心肾系统损害,然而三者之间如何影响以及影响的具体程度仍然存在争议,因此本综述主要概括了糖尿病,分别陈述了包括1型糖尿病、2型糖尿病与心血管之间的相互关联,并讨论了涉及肾脏病的部分。Cardiovascular disease (CVD), diabetes and chronic kidney disease (CKD) are the most common diseases. The existing epidemiological research and clinical research all have evidence to support the correlation among them, and have defined the concept of CMR (cardiac-metabolic-renal disease). The three are interconnected and influence each other, holding significant epidemiological, pathophysiological, and prognostic implications. In previous studies, high glucose can induce damage to the heart and kidney system. However, how and to what extent it affects the heart and kidney system is still controversial. Therefore, this review mainly summarizes diabetes, respectively states the correlation between type 1 diabetes, type 2 diabetes and the cardiovascular system, and discusses the part involving kidney disease.
暂无评论